CA2437844C - Method for increasing leptin levels using nicotinic acid compounds - Google Patents

Method for increasing leptin levels using nicotinic acid compounds Download PDF

Info

Publication number
CA2437844C
CA2437844C CA002437844A CA2437844A CA2437844C CA 2437844 C CA2437844 C CA 2437844C CA 002437844 A CA002437844 A CA 002437844A CA 2437844 A CA2437844 A CA 2437844A CA 2437844 C CA2437844 C CA 2437844C
Authority
CA
Canada
Prior art keywords
nicotinic acid
leptin
ester
medicament
leptin levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002437844A
Other languages
English (en)
French (fr)
Other versions
CA2437844A1 (en
Inventor
Elaine Jacobson
Myron K. Jacobson
Hyuntae Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
University of Arizona
Original Assignee
University of Kentucky Research Foundation
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2437844(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Kentucky Research Foundation, University of Arizona filed Critical University of Kentucky Research Foundation
Publication of CA2437844A1 publication Critical patent/CA2437844A1/en
Application granted granted Critical
Publication of CA2437844C publication Critical patent/CA2437844C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002437844A 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds Expired - Lifetime CA2437844C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08
US60/274,349 2001-03-08
PCT/US2002/007256 WO2002072092A1 (en) 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds

Publications (2)

Publication Number Publication Date
CA2437844A1 CA2437844A1 (en) 2002-09-19
CA2437844C true CA2437844C (en) 2007-05-15

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002437844A Expired - Lifetime CA2437844C (en) 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds

Country Status (12)

Country Link
US (2) US6750234B2 (https=)
EP (1) EP1365762B1 (https=)
JP (1) JP5057353B2 (https=)
CN (1) CN1265792C (https=)
AT (1) ATE409037T1 (https=)
CA (1) CA2437844C (https=)
DE (1) DE60229041D1 (https=)
DK (1) DK1365762T3 (https=)
ES (1) ES2315358T3 (https=)
MX (1) MXPA03008096A (https=)
PT (1) PT1365762E (https=)
WO (1) WO2002072092A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002072092A1 (en) * 2001-03-08 2002-09-19 University Of Kentucky Method for increasing leptin levels using nicotinic acid compounds
JP5204947B2 (ja) * 2002-11-27 2013-06-05 ディーエムアイ バイオサイエンシズ インコーポレイテッド リン酸受容体化合物の使用、ならびにリン酸受容体化合物を含んでいる、薬学的組成物、スキンケア用の組成物、およびキット
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
WO2006044718A2 (en) 2004-10-14 2006-04-27 Flarion Technologies, Inc. Methods and apparatus for determining, communicating and using information which can be used for interference control purposes
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
CN103127111B (zh) * 2005-06-24 2016-02-10 代表亚利桑那大学的亚利桑那校董会 用于治疗头发生长病症比如女性型脱发的方法及可用于此的组合物
EP2462944A3 (en) 2005-08-29 2012-09-12 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8989084B2 (en) 2005-10-14 2015-03-24 Qualcomm Incorporated Methods and apparatus for broadcasting loading information corresponding to neighboring base stations
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US20070253449A1 (en) 2005-12-22 2007-11-01 Arnab Das Methods and apparatus related to determining, communicating, and/or using delay information
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
WO2008026349A1 (fr) * 2006-08-31 2008-03-06 Juridical Foundation Osaka Industrial Promotion Organization Agent thérapeutique destiné au traitement de l'effluvium télogène
PL2120917T3 (pl) * 2007-02-28 2014-09-30 Univ Kentucky Res Found Sposób na łagodzenie działań niepożądanych terapii kwasem retinowym i/lub ulepszanie skuteczności bez zakłócania skuteczności
JP2013516500A (ja) 2010-01-11 2013-05-13 ヒールオア・リミテッド 炎症性疾患および障害を治療するための方法
EP3446689B1 (en) * 2016-04-22 2025-01-08 JC (Wuxi) COMPANY, Inc. Isothiocyanate compound for use in the treatment of hyperbilirubinemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3570598D1 (en) * 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
JP2657583B2 (ja) * 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
EP0815230A2 (en) * 1995-03-20 1998-01-07 Ligand Pharmaceuticals, Inc. MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR
US6015821A (en) * 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
US20040102358A1 (en) * 1997-05-19 2004-05-27 Scivoletto Rosemarie Composition for treating skin conditions
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
DE69919403T2 (de) * 1998-12-01 2005-09-08 The University Of Kentucky Research Foundation Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
WO2002072092A1 (en) * 2001-03-08 2002-09-19 University Of Kentucky Method for increasing leptin levels using nicotinic acid compounds

Also Published As

Publication number Publication date
ATE409037T1 (de) 2008-10-15
EP1365762A4 (en) 2005-05-25
EP1365762A1 (en) 2003-12-03
CA2437844A1 (en) 2002-09-19
US20020128298A1 (en) 2002-09-12
US6750234B2 (en) 2004-06-15
CN1496260A (zh) 2004-05-12
MXPA03008096A (es) 2005-10-05
HK1065941A1 (en) 2005-03-11
WO2002072092A1 (en) 2002-09-19
DE60229041D1 (de) 2008-11-06
US20040198776A1 (en) 2004-10-07
ES2315358T3 (es) 2009-04-01
PT1365762E (pt) 2008-11-27
JP2004519488A (ja) 2004-07-02
JP5057353B2 (ja) 2012-10-24
DK1365762T3 (da) 2008-11-17
EP1365762B1 (en) 2008-09-24
CN1265792C (zh) 2006-07-26

Similar Documents

Publication Publication Date Title
CA2437844C (en) Method for increasing leptin levels using nicotinic acid compounds
US8846039B2 (en) Method for ameliorating pruritus
US5955059A (en) Use of locally applied DNA fragments
ES2371671T3 (es) Uso de ácido fenilbutírico o sales del mismo para tratar el prurito.
Sredni et al. Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras‐dependent up‐regulation of KGF expression
WO2022001784A1 (zh) 谷氨酰胺酶抑制剂在制备治疗银屑病的药物中的应用
Prasad et al. Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells
AU697742B2 (en) Treatment of cytokine growth factor caused disorders
CA2280770C (en) Gene therapy for alleviating erectile dysfunction
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
Smith et al. The role of prostaglandins in triggering the liver regeneration cascade
EP1178801B1 (en) Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders
CA2639904C (en) Use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders, and cosmetic or pharmaceutical composition containing same
CA2573060A1 (en) Asymmetric disulfides and methods of using same
US20070042976A1 (en) Method of treating cosmetic and dermatologic conditions by a demethylating agent
HK1065941B (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
EP1009345A1 (en) Skin aging and wound treatment using cell migration agents
JP2003514855A (ja) カロリー制限の効果を模倣した治療的介入
CA2601999C (en) Method for ameliorating pruritus
KR100953386B1 (ko) 소양증 개선 방법
WO2001028565A1 (en) Remedies for pigmentation and melanocyte proliferation inhibitors
TW202345824A (zh) 氮雜環丁烷衍生物的用途及治療方法
KR20110041104A (ko) 순수 비타민 C, SC-glucan, 미네랄 복합 성분을 함유한 피부 외용제 조성물
KR19980020379A (ko) 사이토킨 성장인자로 인한 질병의 치료방법

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220308